相似文献
1
Successful treatment of acyclovir-resistant herpes simplex virus with intralesional cidofovir.
Arch Dermatol. 2010 Feb;146(2):124-6. doi: 10.1001/archdermatol.2009.363.
2
Treatment of acyclovir-resistant, foscarnet-unresponsive HSV infection with topical cidofovir in a child with AIDS.
Arch Dermatol. 1998 Sep;134(9):1169-70. doi: 10.1001/archderm.134.9.1169.
3
Successful treatment of foscarnet-resistant herpes simplex stomatitis with intravenous cidofovir in a child.
Pediatr Infect Dis J. 2001 Nov;20(11):1083-6. doi: 10.1097/00006454-200111000-00016.
4
Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC).
Clin Infect Dis. 1994 Apr;18(4):570-8. doi: 10.1093/clinids/18.4.570.
5
Long-term follow-up of HIV-infected patients once diagnosed with acyclovir-resistant herpes simplex virus infection.
Int J STD AIDS. 2014 Aug;25(9):676-82. doi: 10.1177/0956462413518034. Epub 2014 Feb 17.
6
Topical cidofovir: a novel treatment for recalcitrant molluscum contagiosum in children infected with human immunodeficiency virus 1.
Arch Dermatol. 2000 Aug;136(8):983-5. doi: 10.1001/archderm.136.8.983.
7
Successful clearance of cutaneous acyclovir-resistant, foscarnet-refractory herpes virus lesions with topical cidofovir in an allogeneic hematopoietic stem cell transplant patient.
J Oncol Pharm Pract. 2013 Jun;19(2):181-5. doi: 10.1177/1078155212448408. Epub 2012 May 25.
8
Successful treatment of an aciclovir-resistant herpes simplex type 2 infection with cidofovir in an AIDS patient.
Br J Dermatol. 2002 Jul;147(1):134-8. doi: 10.1046/j.1365-2133.2002.04747.x.
9
Treatment with intravenous (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]-cytosine of acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with AIDS.
J Infect Dis. 1994 Sep;170(3):570-2. doi: 10.1093/infdis/170.3.570.
10
Successful treatment of an acyclovir- and foscarnet-resistant herpes simplex virus type 1 lesion with intravenous cidofovir.
Clin Infect Dis. 1998 Feb;26(2):512-3. doi: 10.1086/517101.
引用本文的文献
1
Lactobacilli-Derived Postmetabolites Are Broad-Spectrum Inhibitors of Herpes Viruses In Vitro.
Int J Mol Sci. 2024 Dec 25;26(1):74. doi: 10.3390/ijms26010074.
2
Photodynamic Inactivation of Human Herpes Virus In Vitro with Ga(III) and Zn(II) Phthalocyanines.
Viruses. 2024 Dec 18;16(12):1937. doi: 10.3390/v16121937.
3
Cutaneous Applications of the Antiviral Drug Cidofovir: A Review.
J Clin Med. 2024 Apr 23;13(9):2462. doi: 10.3390/jcm13092462.
4
A critical review on antiviral peptides derived from viral glycoproteins and host receptors to decoy herpes simplex virus.
Microb Biotechnol. 2023 Nov;16(11):2036-2052. doi: 10.1111/1751-7915.14342. Epub 2023 Sep 23.
5
Influence of seasonal and geographic variation on the anti-HSV-1 properties and chlorogenic acids content of Sch. Bip.
Front Mol Biosci. 2022 Aug 25;9:961859. doi: 10.3389/fmolb.2022.961859. eCollection 2022.
6
Treatment of acyclovir-resistant herpes simplex virus with intralesional cidofovir.
JAAD Case Rep. 2021 May 26;13:86-89. doi: 10.1016/j.jdcr.2021.05.001. eCollection 2021 Jul.
7
Viral Venereal Diseases of the Skin.
Am J Clin Dermatol. 2021 Jul;22(4):523-540. doi: 10.1007/s40257-021-00606-7. Epub 2021 May 18.
8
A case of an atypical resistant granulomatous HSV-1 and HSV-2 ulceration in an AIDS patient treated with intralesional cidofovir.
SAGE Open Med Case Rep. 2019 May 2;7:2050313X19847029. doi: 10.1177/2050313X19847029. eCollection 2019.
9
HIV-Related Skin Disease in the Era of Antiretroviral Therapy: Recognition and Management.
Am J Clin Dermatol. 2019 Jun;20(3):423-442. doi: 10.1007/s40257-019-00422-0.
10
First Impressions-the Potential of Altering Initial Host-Virus Interactions for Rational Design of Herpesvirus Vaccine Vectors.
Curr Clin Microbiol Rep. 2018 Mar;5(1):55-65. doi: 10.1007/s40588-018-0082-1. Epub 2018 Jan 27.
本文引用的文献
1
Intralesional cidofovir does not increase the risk of laryngeal dysplasia or laryngeal carcinoma.
Int J Pediatr Otorhinolaryngol. 2008 Oct;72(10):1581-2; author reply 1583. doi: 10.1016/j.ijporl.2008.05.013. Epub 2008 Jul 3.
2
Adult intralesional cidofovir therapy for laryngeal papilloma: a 10-year perspective.
Arch Otolaryngol Head Neck Surg. 2008 May;134(5):497-500. doi: 10.1001/archotol.134.5.497.
3
Side-effects of cidofovir in the treatment of recurrent respiratory papillomatosis.
Eur Arch Otorhinolaryngol. 2008 Aug;265(8):871-9. doi: 10.1007/s00405-008-0658-0. Epub 2008 May 6.
4
1% topical cidofovir used as last alternative to treat viral infections.
J Eur Acad Dermatol Venereol. 2008 Feb;22(2):249-50. doi: 10.1111/j.1468-3083.2007.02304.x.
5
Cidofovir: to use or not to use?
Curr Opin Otolaryngol Head Neck Surg. 2008 Feb;16(1):86-90. doi: 10.1097/MOO.0b013e3282f43408.
6
Intravenous cidofovir-induced resolution of disfiguring cutaneous human papillomavirus infection.
J Am Acad Dermatol. 2006 Sep;55(3):533-6. doi: 10.1016/j.jaad.2006.01.007.
7
Treatment of verruca vulgaris with topical cidofovir in an immunocompromised patient: a case report and review of the literature.
Transpl Infect Dis. 2005 Sep-Dec;7(3-4):158-61. doi: 10.1111/j.1399-3062.2005.00099.x.
8
Management of acyclovir-resistant herpes simplex virus.
Dermatol Clin. 2003 Apr;21(2):311-20. doi: 10.1016/s0733-8635(02)00093-1.
9
Topical cidofovir for the treatment of dermatologic conditions: verruca, condyloma, intraepithelial neoplasia, herpes simplex and its potential use in smallpox.
Dermatol Clin. 2003 Apr;21(2):301-9. doi: 10.1016/s0733-8635(02)00116-x.
10
Bioavailability and metabolism of cidofovir following topical administration to rabbits.
Antiviral Res. 1997 Jul;35(2):113-22. doi: 10.1016/s0166-3542(97)00022-3.
Zotero 插件